Flow cytometric analysis of PBMCs from healthy volunteers treated with either placebo or FL for 14 consecutive days.
(A) Correlation of lineage-specific marker expression (CD3, CD14, CD19, and CD56) with CD33 or HLA-DR expression. (B) Correlation of CD14 with CD11c expression. (C) Expression of cell surface molecules on CD11c+ CD14− PBMCs from FL-treated individuals. CD1a, CD1b/c, CD2, CD4, CD5, CD8α, CD11b, CD40, CD80, CD83, CD86, HLA-DR, GM-CSFRα, IL-3Rα, and MMR expression are presented as the shaded histograms. Unshaded histograms represent CD11c+ CD14− cells incubated with isotype-matched controls. (D) Expression of CD5 and MMR on gated CD11c+ CD14− PBMCs. Data are presented from a representative individual treated with FL at 75 μg · kg−1 · d−1. Similar profiles were observed with treatment at 10, 25, 50, and 100 μg · kg−1 · d−1.
